OVERVIEW OF THE SECTOR PHARMA

Statistics, news & updates: everything you need to know about the Pharmaceutical Industry in India

Pharmaceutical Industry India
  • Summary
  • Industry Clusters
  • Growth Drivers
  • Key Players
  • Market Stats

Summary

Almost four decades back, the Indian Pharmaceutical industry was at a nascent stage, and the Indian Government set up a Patent Act at that time and since then provided additional support to help the Industry grow. Presently, India is the largest producer of generic drugs worldwide with 20% global exports and the Pharmaceutical Industry is one of the most profitable in India. The Government wants the Industry to become the largest in the world. Branded products dominate the market and India has the largest number of USDA compliant plants outside of the US. Many international companies in this sector have set their foot into India. Still, it offers great potential for companies wanting to enter the Indian Pharmaceutical market, as the Industry is forecasted to outperform the Global Industry and rank 3rd worldwide by 2020. Additionally, India offers a large pool of well-qualified scientists for this sector.

Please see our latest Pharmaceutical Industry Newsletter here!

Map- Industry Clusters

Map- Industry Clusters - Pharma

Growth Drivers

  • Significantly lower production costs as compared to US and Europe
  • Investments of over $200 billion in Pharmaceutical infrastructure expected until 2024
  • Expected revenues of $45 billion by 2020
  • Supportive Government policies and governmental focus on improving quality in Pharmaceuticals
  • Increasing penetration of chemists in rural India
  • India’s patient pool is expected to increase to over 20% in the next 10 years, mainly due to the rise in population

Key Players in India

International

  • Pfizer, P&G, AstraZeneca, Johnson&Johnson, GSK, Novartis, Natco Pharma Ltd., Merck, Nipro, Sanofi

National

  • Dr. Reddy’s, Lupin, Sun Pharma, Cadila Pharma, Cipla, Torrent Pharmaceuticals, IPCA, Glenmark Pharmaceuticals, Biocon

 

updated in May 2017

Market Stats

  • Generic Pharma sales in 2016 reached $26,1 billion
  • Biopharma is the largest sub-sector of the industry
  • The Industry accounts for 10% of the global Pharmaceutical volume
  • Cumulative FDI inflows of $14.49 billion between April 2000 – September 2016
  • Expected to expand at a CAGR of 12.89% over 2015–2020 to reach $55 billion